Evonik Industries has started the planning stage for the construction
of an additional world-scale plant complex in Singapore. The facility, which
will produce the amino acid DLmethionine for animal nutrition, will have an
annual production capacity of 150,000 metric tons and is expected to start
operations in 2019. It still requires authorisation from the Evonik committees.
With this decision Evonik follows the global megatrends of health and nutrition, which are driving the growth of the DL-methionine business. With the timely and demand driven expansion of capacities over the past few years Evonik has continuously accompanied this strong market growth.
“We are convinced that the market for DL-methionine will
continue to show dynamic growth, and we want to contribute to meeting the
global demand for this product, which is indispensable for efficient and sustainable
animal nutrition worldwide," says Klaus Engel, the Chairman of the Evonik
Executive Board.
Evonik sells DLmethionine under the brand name MetAMINO®.
Evonik’s most recent methionine plant took up its operations in Singapore in the fourth quarter of 2014 after a two-year construction period—precisely as planned—and operations are utilised according to plan.
"The new complex will allow us to accompany market growth and further strengthen relations. As a reliable partner to our customers, we are of the strong conviction to realise this project in the given time frame as well," said Dr Reiner Beste, the Chairman of the Board of Management at Evonik Nutrition & Care GmbH.
In its new, backward-integrated production complex, Evonik will also produce all associated strategically relevant precursors.
The construction of the plant complex is planned next to the existing Evonik methionine plant on Jurong Island in Singapore. The location in Singapore allows Evonik to serve especially Asian growth markets well. The specialty chemicals company produces DL-methionine at world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.
DL-methionine is an essential amino acid, and must therefore
be supplied in the diet. As a feed additive, it contributes to the efficient,
healthy and environmentally friendly nutrition of livestock, particularly
poultry and swine.
Population growth and rising affluence are resulting in increased meat consumption in many parts of the world, driving up the demand for methionine. The addition of methionine and other amino acids can significantly lower the crude protein content of animal feed. This in turn benefits the environment by alleviating resource consumption, greenhouse effect, eutrophication, and acidification potential.
Evonik produces and markets four essential amino acids for modern animal nutrition: MetAMINO® (DL-methionine), Biolys® (L-lysine), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). The company provides innovative services and products in over 100 countries, making a valuable contribution to the profitability of its customers and to healthy, environmentally friendly and sustainable animal nutrition.
Visit the Evonik site HERE.
With this decision Evonik follows the global megatrends of health and nutrition, which are driving the growth of the DL-methionine business. With the timely and demand driven expansion of capacities over the past few years Evonik has continuously accompanied this strong market growth.
“We are convinced that the market for DL-methionine will
continue to show dynamic growth, and we want to contribute to meeting the
global demand for this product, which is indispensable for efficient and sustainable
animal nutrition worldwide," says Klaus Engel, the Chairman of the Evonik
Executive Board.
Evonik sells DLmethionine under the brand name MetAMINO®.
Evonik’s most recent methionine plant took up its operations in Singapore in the fourth quarter of 2014 after a two-year construction period—precisely as planned—and operations are utilised according to plan.
"The new complex will allow us to accompany market growth and further strengthen relations. As a reliable partner to our customers, we are of the strong conviction to realise this project in the given time frame as well," said Dr Reiner Beste, the Chairman of the Board of Management at Evonik Nutrition & Care GmbH.
In its new, backward-integrated production complex, Evonik will also produce all associated strategically relevant precursors.
The construction of the plant complex is planned next to the existing Evonik methionine plant on Jurong Island in Singapore. The location in Singapore allows Evonik to serve especially Asian growth markets well. The specialty chemicals company produces DL-methionine at world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.
 |
| Singapore (Image: Swaminathan) |
Population growth and rising affluence are resulting in increased meat consumption in many parts of the world, driving up the demand for methionine. The addition of methionine and other amino acids can significantly lower the crude protein content of animal feed. This in turn benefits the environment by alleviating resource consumption, greenhouse effect, eutrophication, and acidification potential.
Evonik produces and markets four essential amino acids for modern animal nutrition: MetAMINO® (DL-methionine), Biolys® (L-lysine), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). The company provides innovative services and products in over 100 countries, making a valuable contribution to the profitability of its customers and to healthy, environmentally friendly and sustainable animal nutrition.
Visit the Evonik site HERE.
The Global Miller
This blog is maintained by The Global Miller staff and is supported by the magazine GFMT
which is published by Perendale Publishers Limited.
For additional daily news from milling around the world: global-milling.com
No comments:
Post a Comment